Medicare's proposed dialysis cut takes a toll on device makers

Tue, 07/02/2013 - 3:09pm
Mass Device

Medical device makers DaVita and Fresenius suffer Wall Street losses amid Medicare's proposal to cut about 9% from dialysis reimbursements.

healthcare and spending

Dialysis technology makers slid hard today after the Center for Medicare & Medicaid Services proposed a reimbursement decrease of more than 9% for 2014.

As of about 2:45 p.m. DaVita Inc. (NYSE:DVA) was down 5.8% to $114.16 and Fresenius (NYSE:FMS) was down 9.8% to $32.03.

The cuts, part of a new federal budget agreement designed in part to stem over-spending on certain drugs, also proposed a 9.4% cut to reimbursements for dialysis. The budget proposal will undergo a period of public comment and review before it's slated to take effect.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.